Cryoport (NASDAQ:CYRX – Get Free Report) posted its earnings results on Wednesday. The company reported ($0.31) earnings per share for the quarter, hitting analysts’ consensus estimates of ($0.31), Briefing.com reports. Cryoport had a negative return on equity of 8.74% and a negative net margin of 19.73%. The business had revenue of $56.16 million for the quarter, compared to analyst estimates of $55.24 million. During the same period in the previous year, the firm earned ($0.15) EPS. The firm’s revenue was down 7.1% compared to the same quarter last year.
Cryoport Stock Down 2.7 %
Shares of Cryoport stock traded down $0.30 on Friday, reaching $11.00. 209,771 shares of the stock were exchanged, compared to its average volume of 552,819. The company has a debt-to-equity ratio of 0.78, a quick ratio of 13.82 and a current ratio of 14.54. The firm’s 50 day moving average is $12.27 and its 200-day moving average is $15.94. Cryoport has a one year low of $9.00 and a one year high of $26.01.
Insider Activity at Cryoport
In other Cryoport news, insider Jerrell Shelton sold 26,875 shares of the company’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $14.27, for a total transaction of $383,506.25. Following the completion of the sale, the insider now directly owns 632,424 shares in the company, valued at $9,024,690.48. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. 10.50% of the stock is currently owned by insiders.
Institutional Trading of Cryoport
Analysts Set New Price Targets
Several equities analysts have recently weighed in on CYRX shares. B. Riley dropped their price objective on shares of Cryoport from $30.00 to $22.00 in a research report on Thursday, July 13th. SVB Securities downgraded Cryoport from an “outperform” rating to a “market perform” rating and decreased their target price for the company from $30.00 to $10.00 in a research report on Thursday, July 13th. SVB Leerink cut Cryoport from an “outperform” rating to a “market perform” rating in a report on Thursday, July 13th. Morgan Stanley started coverage on Cryoport in a report on Thursday, August 17th. They issued an “equal weight” rating and a $16.00 price objective on the stock. Finally, UBS Group cut shares of Cryoport from a “buy” rating to a “neutral” rating and reduced their target price for the company from $28.00 to $17.00 in a research report on Tuesday, July 18th. Five equities research analysts have rated the stock with a hold rating and three have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Cryoport has an average rating of “Hold” and a consensus price target of $19.88.
Cryoport Company Profile
Cryoport, Inc provides temperature-controlled supply chain solutions in biopharma/pharma, animal health, and human reproductive medicine markets in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments: Global Logistics Solutions and Global Bioservices. The company offers Cryoport Express Shippers; Cryoport ELITE -80°C Gene Therapy Shipper; Cryoport ELITE Cryosphere Shipper; Cryoport consulting services, including physical, thermal, and shipping qualifications of shipping systems and/or packaging to developing custom packaging solutions; and Cryoport bioservices, such as controlled temperature storage, fulfilment, kit production, secondary packaging, labelling of therapeutic products, and GMP raw materials storage services.
- Five stocks we like better than Cryoport
- What Are Dividends? Buy the Best Dividend Stocks
- Data giants MongoDB and Snowflake just got upgraded
- How to Invest and Trade Chinese Stocks
- Plug Power at tipping point; it’s make or break time for hydrogen
- How to Invest in Cybersecurity
- Palantir’s Q3 earnings beat: Time to buy despite analyst caution?
Receive News & Ratings for Cryoport Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cryoport and related companies with MarketBeat.com's FREE daily email newsletter.